Oncopeptides AB (publ) announced that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti. The recommendation from CIPM, formally the Spanish Interministerial Commission on Drug Pricing (Spanish: Comisión Interministerial de Precios de los Medicamentos) is a major step forward in Oncopeptides' efforts to gain market access in Spain, however well ahead of presumed timelines. The recommendation also reflects the innovation of melflufen and is in line with the financial projections of the company. Following the administrative phase of the process that now commences, a full launch of Pepaxti in Spain could take place already during the second half of 2024. The CIPM's positive proposal will now be turned into a resolution proposal by the Ministry of Health, needing Oncopeptides' approval. Once approved, a final financing resolution will be issued, and the drug will be listed in the Spanish healthcare registry, allowing healthcare professionals to prescribe it. Oncopeptides will discuss this event during the presentation of its end-year report on
February 27, and communicate further once the agreement with the Spanish Ministry of Health has been finalized.